Abstract
A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.
Translated title of the contribution | Evaluation of platelet aggregation, some blood clotting parameters, and the lipid profile in patients treated with Suloctidyl |
---|---|
Original language | Italian |
Pages (from-to) | 143-152 |
Number of pages | 10 |
Journal | Gazzetta Medica Italiana |
Volume | 141 |
Issue number | 4 |
Publication status | Published - 1982 |
ASJC Scopus subject areas
- Medicine(all)